A Multicenter Phase 1 Study of EMD 525797 (DI17E6), a Novel Humanized Monoclonal Antibody Targeting αv Integrins, in Progressive Castration-resistant Prostate Cancer with Bone Metastases After Chemotherapy
Authors:
- 1 May 2014
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 65 (5) , 897-904
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Integrin Targeted Delivery of ChemotherapeuticsTheranostics, 2011
- Prostate cancer specific integrin αvβ3 modulates bone metastatic growth and tissue remodelingOncogene, 2007
- Alpha-v Integrins as Therapeutic Targets in OncologyCancer Investigation, 2007
- First‐ and second‐line chemotherapy with docetaxel or mitoxantrone in patients with hormone‐refractory prostate cancerCancer, 2006
- αvβ Integrins Play an Essential Role in BMP-2 Induction of Osteoblast DifferentiationJournal of Bone and Mineral Research, 2005
- Androgen-Independent Prostate Cancer Is a Heterogeneous Group of DiseasesCancer Research, 2004
- Emerging views of integrin signaling: Implications for prostate cancerJournal of Cellular Biochemistry, 2003
- Role of integrins in cell invasion and migrationNature Reviews Cancer, 2002
- Multiple Roles of Integrins in Cell MotilityExperimental Cell Research, 2000
- Integrin expression in human boneJournal of Bone and Mineral Research, 1993